BD Q1 FY25 earnings: Strong growth, higher guidance, and biosciences separation strategy
Becton, Dickinson and Company, a global leader in medical technology, reported a 9.8% year-over-year revenue increase in its first-quarter fiscal 2025 earnings, reaching $5.2 billion. ... Read More
BD to acquire Edwards Lifesciences’ Critical Care product group for $4.2bn
In a major strategic move, Becton, Dickinson and Company (NYSE: BDX), widely known as BD, has entered into a definitive agreement to acquire the Critical ... Read More